Evidence map›Paper›PMID 35019774›Full record

ArticleMicrobiology spectrum2022

Variants of Tn

Riti Mann, Rayane Rafei, Cindy Gunawan, Christopher J Harmer, Mohammad Hamidian

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Clonal dissemination of carbapenem-resistant ST477Frontiers in cellular and infection microbiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. ISMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Coexistence ofFrontiers in cellular and infection microbiology · 2023
    Article
  15. Review
  16. Article
  17. Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022
    Review
  18. Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-ResistantEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Riti MannThe iThree Institute, University of Technology Sydney, Ultimo, New South Wales, Australia.
Rayane RafeiLaboratoire Microbiologie Santé et Environnement (LMSE), Doctoral School of Science & Technology, Faculty of Public Health, Lebanese University, Tripoli, Lebanon.
Cindy GunawanThe iThree Institute, University of Technology Sydney, Ultimo, New South Wales, Australia.
Christopher J HarmerSchool of Life and Environmental Sciences, The University of Sydneygrid.1013.3, Sydney, New South Wales, Australia.ORCID 0000-0003-1486-454X
Mohammad HamidianThe iThree Institute, University of Technology Sydney, Ultimo, New South Wales, Australia.ORCID 0000-0002-3614-7261
University of Technology Sydney · AULebanese University · LBThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem resistance in Acinetobacter baumannii is primarily due to the global spread of two main clones that carry

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAmikacinAnti-Bacterial Agentsbeta-LactamasesCarbapenemsDrug Resistance, BacterialGenome, BacterialMacrolidesMeropenemPhylogenySequence AlignmentAmikacinAnti-Bacterial Agentsbeta-LactamasesCarbapenemsMacrolidesMeropenemAcinetobacter baumanniiaminoglycoside resistanceantibiotic resistanceaphA6blaNDMcarbapenem resistanceTn6924

Identifiers

PMID35019774
PMCPMC8754128
OpenAlexW4206123984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.